Strategic funding Locanabio has secured $156M in funding and is actively pursuing partnerships and investor-backed growth, indicating a willingness to engage with strategic collaborators and potential co-development arrangements.

Duchenne interest CureDuchenne Ventures investment signals strong interest from neuromuscular disease-focused funds, presenting an entry point for partnerships around Duchenne muscular dystrophy strategies and exon-skipping programs.

Vectorized platform Recent launch of the Vectorized snRNA Platform and presentation of preclinical data highlight a differentiated RNA-targeting modality that could be attractive for pharma partners seeking durable, non-DNA-altering genetic medicines.

Rare disease focus Early programs targeting rare genetic neuromuscular and neurodegenerative diseases align with potential clients in specialty biotech and CROs seeking niche gene therapy and RNA-targeting collaborations.

Leadership network A strong board and scientific advisory network paired with experienced executives in strategy, finance, and clinical development present opportunities for sponsored research, consultancy, and joint development conversations with potential buyers or partners.